• Placental syndromes at high risk pregnancy considerably of endothelial dysfunction: modern concepts and methods of correction
To content

Placental syndromes at high risk pregnancy considerably of endothelial dysfunction: modern concepts and methods of correction

HEALTH OF WOMAN.2015.5(101):83–86
 

Placental syndromes at high risk pregnancy considerably of endothelial dysfunction: modern concepts and methods of correction
 

Davydova I. U., Limanskaya A., Dvulit M., Ogorodnyk A.

SI «Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine», Kiev
 

The article covers the mechanisms of placental syndromes forming in terms of the formation of placental dysfunction. Defined the main growth factors as diagnostic markers of the risk of placental syndromes, particularly pre-eclampsia. The main biomarkers for preeclampsia attributed VEGF, sFLT, PlGF should be determined in 1 trimester of pregnancy. Defined the role of prevention endothelial dysfunction in preconception period and during the early period of gestation. The effect of Tivortin on pregnancy and development placental syndromes among 23 pregnant women with congenital heart diseases and heart failure. It was found that use of the Tivortin in preconception and early gestation periods to avoid the development of placental syndromes in the later stages of pregnancy.
 

Key words: placental syndrome, preeclampsia, placental dysfunction, heart failure, treatment Tivortin.
 

REFERENCES

1. Agatisa PK, Ness RB, Roberts JM et al. 2004. Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. Am J Physiol Heart Circ Physiol. 286:H1389–H1393. http://dx.doi.org/10.1152/ajpheart.00298.2003; PMid:15020302

2. Bellamy L, Casas JP, Hingo-rani AD et al. 2007. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 335:974–977. http://dx.doi.org/10.1136/bmj.39335.385301.BE; PMid:17975258 PMCid:PMC2072042

3. Carty DM, Delles C, Dominiczak AF. 2010. Preeclampsia and future maternal health. J Hypertens. 28:1349–1355. http://dx.doi.org/10.1097/HJH.0b013e32833a39d0; PMid:20467325

4. Carr DB, Newton KM, Utzschneider KM et al. 2009. Preeclampsia and risk of developing subsequent diabetes. Hypertens Pregnancy 28:435–447. http://dx.doi.org/10.3109/10641950802629675; PMid:19843005

5. Cordeiro A et al. 07.09.2014. Relevance of genomic imprinting in intrauterine human growth expression of CDKN1C, H19, IGF2, KCNQ1 and PHLDA2 imprinted genes. Journal of Assisted Reproduction and Genetics. http://dx.doi.org/10.1007/s10815-014-0278-0; PMCid:PMC4171407

6. Lampinen KH, Ronnback M, Kaaja RJ et al. 2006. Impaired vascular dilatation in women with a history of pre-eclampsia. J Hypertens. 24:751–756. http://dx.doi.org/10.1097/01.hjh.0000217859.27864.19; PMid:16531805

7. Levine RJ, Maynard SE, Qian C et al. 2004. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 350:672–683. http://dx.doi.org/10.1056/NEJMoa031884; PMid:14764923

8. Libby G, Murphy DJ, McEwan NF et al. 2007. Pre-eclampsia and the later development of type 2 diabetes in mothers and their children: an intergenerational study from the Walker cohort. Diabe-tologia. 50:5 23–530.

9. Lloyd-Jones D, Adams RJ, Brown TM et al. 2010. Heart disease and stroke statistics-2010 update: a report from the American HeartAssociation.Circulation 121:e46–e215. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192667; PMid:20019324

10. Maynard SE, Moore Simas TA, Solitro MJ et al. 2008. Circulating angiogenic factors in singleton vs multiple-gestation pregnancies. Am J Obstet Gynecol. 198:200.e1–200.e7. http://dx.doi.org/10.1016/j.ajog.2007.08.042; PMid:18226624

11. McDonald SD, Malinowski A, Zhou Q et al. 2008. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J. 156:918–930. http://dx.doi.org/10.1016/j.ahj.2008.06.042; PMid:19061708

12. Ramsay JE, Stewart F, Greer IA et al. 2003. Microvascular dysfunction:a link between pre-eclampsia and maternal coronary heart disease. BJOG 110:1029–1031. http://dx.doi.org/10.1111/j.1471-0528.2003.02069.x; PMid:14592589

13. Sheppard SJ, Khalil RA. 2010. Risk factors and mediators of the vascular dysfunction associated with hypertension in pregnancy. Cardiovasc Hematol Disord Drug Targets 10:33–52. http://dx.doi.org/10.2174/187152910790780096

14. Venkatesha S, Toporsian M, Lam C et al. 2006. Soluble endoglin contributes to the pathogenesis of preeclampsia published correction appears in Nat Med. 12:862. Nat Med.2006. 12:642–649. http://dx.doi.org/10.1038/nm1429; http://dx.doi.org/10.1038/nm0706-862c; PMid:16751767